Montag & Associates’s Corcept Therapeutics CORT Stock Holding History

Montag & Associates’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.1K	Hold	542	–	–	﹤0.01%	606
2026 Q1	$21.8K	Hold	542	–	–	﹤0.01%	675
2025 Q4	$18.9K	Hold	542	–	–	﹤0.01%	707
2025 Q3	$45K	Hold	542	–	–	﹤0.01%	612
2025 Q2	$39.8K	Hold	542	–	–	﹤0.01%	613
2025 Q1	$61.9K	Hold	542	–	–	﹤0.01%	569
2024 Q4	$27.3K	Hold	542	–	–	﹤0.01%	686
2024 Q3	$25.1K	Hold	542	–	–	﹤0.01%	708
2024 Q2	$17.6K	Hold	542	–	–	﹤0.01%	718
2024 Q1	$13.7K	Hold	542	–	–	﹤0.01%	736
2023 Q4	$17.6K	Hold	542	–	–	﹤0.01%	705
2023 Q3	$14.8K	Hold	542	–	–	﹤0.01%	696
2023 Q2	$12.1K	Hold	542	–	–	﹤0.01%	730
2023 Q1	$11.7K	Hold	542	–	–	﹤0.01%	727
2022 Q4	$11K	Hold	542	–	–	﹤0.01%	725
2022 Q3	$14K	Hold	542	–	–	﹤0.01%	690
2022 Q2	$13K	Hold	542	–	–	﹤0.01%	676
2022 Q1	$12K	Hold	542	–	–	﹤0.01%	706
2021 Q4	$11K	Hold	542	–	–	﹤0.01%	718
2021 Q3	$11K	Hold	542	–	–	﹤0.01%	720
2021 Q2	$12K	Hold	542	–	–	﹤0.01%	711
2021 Q1	$13K	Hold	542	–	–	﹤0.01%	706
2020 Q4	$14K	Buy	+542	New	+$11.4K	﹤0.01%	671

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Montag & Associates's CORT Position: Q2 2026 in Review

Montag & Associates held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 542 shares worth $47.1K. The position accounts for ﹤0.01% of the portfolio, ranked #606.

Montag & Associates first reported a position in CORT in Q4 2020 and has held it in 23 quarters since. The position peaked at $61.9K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Montag & Associates held 542 shares of Corcept Therapeutics worth $47.1K as of Q2 2026.
Montag & Associates left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Montag & Associates's portfolio in Q2 2026, its #606 holding.
Montag & Associates first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 23 quarters since.
Montag & Associates's Corcept Therapeutics position peaked at $61.9K in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.